TISSUE ENGINEERING AND REGENERATIVE MEDICINE
|
|
- Cody Lewis
- 6 years ago
- Views:
Transcription
1 TISSUE ENGINEERING AND REGENERATIVE MEDICINE A Phase II Trial of Autologous Transplantation of Bone Marrow Stem Cells for Critical Limb Ischemia: Results of the Naples and Pietra Ligure Evaluation of Stem Cells Study ALESSANDRO SCHIAVETTA, a CIRO MAIONE, b CHIARA BOTTI, b GENNARO MARINO, a STEFANO LILLO, b ALBERTO GARRONE, a LORELLA LANZA, a STEFANO PAGLIARI, a ANDREA SILVESTRONI, b GIUSEPPE SIGNORIELLO, c VINCENZO SICA, b GILDA COBELLIS b Key Words. Adult human bone marrow Adult stem cells Angiogenesis Autologous stem cell transplantation Bone marrow transplant Stem/progenitor cell Transplantation Vascular development a Department of Vascular Surgery, Azienda Ospedaliera Santa Corona, Pietra Ligure, Italy; Departments of b General Pathology and c Public Health, Second University of Naples, Naples, Italy Correspondence: Alessandro Schiavetta, M.D., Azienda Ospedaliera Santa Corona, Via XXV Aprile 38, Pietra Ligure, Savona, Italy. Telephone: ; Fax: ; aleschiavetta@libero.it; or Vincenzo Sica, M.D., Department of General Pathology, Seconda Università di Napoli, Via L. De Crecchio, 7, 80138, Napoli, Italy. Telephone: ; Fax: ; vincenzo. sica@unina2.it; or Gilda Cobellis, M.D., Ph.D., Department of General Pathology, Seconda Università di Napoli, Via L. De Crecchio, 7, 80138, Napoli, Italy. Telephone: ; Fax: ; g.cobellis@ unina2.it Received March 1, 2012; accepted for publication June 6, 2012; first published online in SCTM EXPRESS July 6, AlphaMed Press /2012/$20.00/ /sctm ABSTRACT Critical limb ischemia (CLI) is a vascular disease affecting lower limbs, which is going to become a demanding challenge because of the aging of the population. Despite advances in endovascular therapies, CLI is associated with high morbidity and mortality. Patients without direct revascularization options have the worst outcomes. To date, 25% 40% of CLI patients are not candidates for surgical or endovascular approaches, ultimately facing the possibility of a major amputation. This study aimed to assess the safety and efficacy of autologous bone marrow (BM) transplantation performed in no-option patients, in terms of restoring blood perfusion by collateral flow and limb salvage. A multicenter, prospective, not-controlled phase II study for no-option CLI patients was performed. Patients were subjected to intra-arterial infusion of autologous bone marrow and followed for 12 months after the treatment. Variation of blood perfusion parameters, evaluated by laser Doppler flowmetry or transcutaneous oximetry, was set as the primary endpoint at 12 months after treatment and amputation-free survival as the secondary endpoint. Sixty patients were enrolled and treated with BM transplantation, showing improvement in objective and subjective measures of perfusion. Furthermore, survival analysis demonstrated improved amputation-free survival rates (75.2%) at 12 months after the treatment. This study provides further evidence that autologous bone marrow transplantation is well tolerated by CLI patients without adverse effects, demonstrating trends toward improvement in perfusion and reduced amputation rate, confirming the feasibility and safety of the procedure. STEM CELLS TRANSLATIONAL MEDICINE 2012;1: INTRODUCTION Peripheral arterial disease (PAD) is a common circulatory problem. In 2010 almost 18 million U.S. citizens suffered from PAD. Reflecting the aging population, this number is projected to increase to 21 million by Critical limb ischemia (CLI), the most severe and deadly form of the disease, currently affects million of those with PAD. By 2020, the U.S. prevalence of CLI is forecast to grow to between 3.6 and 4.5 million. Among PAD patients, approximately 1% 3% will develop CLI [1]. The clinical course of PAD patients without CLI is generally stable; on the other hand, the prognosis of CLI is poor: according to the TASC II Guidelines [2], after 1 year 30% of patients with CLI will lose a leg and 25% will die. Approximately 25% 40% of CLI patients are not candidates for either surgical or endovascular approaches because of high operative risk or unfavorable vascular involvement, thus leaving a large percentage of patients without any valid therapeutic option. Therefore, new strategies are needed to offer a viable therapy to this increasing number of patients. Several years ago, a step forward was taken in understanding the mechanisms for neovascularization. In 1997, Asahara et al. [3] and Shi et al. [4] identified a class of bone marrow-derived circulating endothelial progenitor cells that contribute to angiogenesis and/or vasculogenesis in ischemic tissue. Since then, numerous studies have reported the capability of stem and progenitor cell types, delivered locally into ischemic tissue, to reduce ischemic damage effects [5, 6]. Subsequently, the use of progenitor cellbased therapies in patients affected by PAD STEM CELLS TRANSLATIONAL MEDICINE 2012;1:
2 Schiavetta, Maione, Botti et al. 573 and/or CLI emerged as a new approach for the treatment of ischemic conditions [7]. Encouraging results of several clinical studies have rapidly demonstrated the beneficial effect of autologous bone marrow mononuclear cell (BM-MNC) transplantation to patients affected by CLI. Clinical benefits were reported from these trials, showing improvement in objective and subjective measures of perfusion (i.e., transcutaneous oximetry [TcPO 2 ], laser Doppler flowmetry [LDF], pain reduction, increase of total walking distance [TWD], and decreased rate of amputation) [7 44]. However, the majority of these studies were case series, with few randomized and controlled trials. Robust trials for cellular therapy in CLI are complicated by ethical reasons, severe comorbidities, challenges of blinding, inclusion criteria, and choice of outcome measures. The primary objective of our trial was to further assess the safety of intra-arterial autologous bone marrow transplantation in CLI patients and the efficacy of this treatment in terms of perfusion parameters and amputation-free survival. Table 1. Eligibility criteria of the Naples and Pietra Ligure Evaluation of Stem Cells study Inclusion criteria Exclusion criteria Age 18 and 80 years Rutherford category 6 Severe PAD (Rutherford category History of neoplasm or 3, 4, or 5) malignancy in the past 5 years Not eligible for surgical or Life expectancy of less than 1 endovascular revascularization Written informed consent year Hgb 10 g/dl Renal insufficiency (serum creatinine 1.8 mg/dl) Known infections Liver function impairment (AST or ALT 60 mg/dl) Neutrophil count 2,000/mm 3 Platelets 100,000/mm 3 Lost at follow-up Current smoker Pregnancy Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; Hgb, hemoglobin; PAD, peripheral artery disease. MATERIALS AND METHODS Study Design The Naples and Pietra Ligure Evaluation of Stem Cells (NAPLES) study was designed as a multicenter, prospective, nonrandomized phase II trial. Patients enrolled in this trial were affected by Rutherford category 3, 4, or 5 PAD (disabling intermittent claudication or CLI with or without tissue loss) who were not candidates for surgical or endovascular revascularization or who had had failed attempts at revascularization. We decided to set a nonrandomized phase II trial because the majority of enrolled subjects were no-option patients, in whom the progression of the disease is well-defined and amputation is the only treatment option available, as previously reported [2]. Therefore, on the basis of observations done by us and others, we believed that an untreated control group was unnecessary. The protocol was approved by the ethics committees of the participating hospitals, the Seconda Università di Napoli and the Azienda Ospedaliera S. Corona di Pietra Ligure, and registered at the European Trials Registration (EudraCT ). Written informed consent for participation was obtained from all patients. The patients treated in Naples are referred to as group 1 (group evaluated with LDF) and the patients treated in Pietra Ligure as group 2 (group evaluated with TcPO 2 ). Eligibility Criteria Eligibility criteria are listed in Table 1. Treatment Procedure A total volume of 105 ml of bone marrow (BM) aspirate was obtained from all patients from posterior iliac crest puncture with a 15-gauge needle, under local anesthesia and smooth conscious sedation. Five milliliters of BM aspirate was kept for research purposes. The remaining BM aspirate (100 ml) was immediately added to sodium heparin (2,000 units) in 20 ml of normal saline and filtered (bone marrow collection kit 4R2104; Fenwal Inc., Lake Zurich, IL, to remove large particulate matter, such as fat, bone chips, and clots. The BM aspirate was then ready for intra-arterial direct infusion ipsilateral to the affected leg through a 4 French introducer placed through common femoral artery into external iliac artery under the control of a peristaltic pump at 150 ml/hour or slowly by direct hand injection. Forty-five days later all the patients underwent a second procedure exactly like the first one. Patients were discharged on the first postoperative day; scheduled for 3, 6, 12, and 24 months follow-up; and given oral L-arginine, 3 g/day, to take for 4 months after the first transplant. Follow-up consisted of clinical evaluation and laser Doppler flowmetry (Periflex PF2B; Perimed AB, Stockholm, Sweden, in group 1 patients or transcutaneous oximetry (TCM400; Radiometer Medical ApS, Brønshøj, Denmark, in group 2 patients. LDF and TcPO 2 were used as noninvasive techniques for assessing microvascular blood flow and tissue oxygen tension after autologous bone marrow transplantation. LDF was performed at a stable room temperature (25 C) after 30 minutes of acclimatization in a supine position at rest. We started the measurements at least 5 minutes after placement of the probe to ensure a stable flux measurement. The probe was positioned on the third distal dorsum of the foot of the affected limb, which underwent the infusion of BM. TcPO 2 was evaluated in patients at rest in a supine position and at a stable room temperature, considering the values obtained 15 minutes after the beginning of the measurement. The probe position was marked with a dermographic pen or was photographed to place the probe in the same position during the subsequent controls. Each measurement was performed three times and averaged. Baseline measurements were determined before transplantation, and the follow-up was performed at intervals of 6 and 12 months after the treatment. Endpoints Because no gold-standard endpoints have been established for such clinical trials, we decided to set as the primary endpoint the variation of blood perfusion parameters measured by LDF (group 1) or TcPO 2 (group 2) at 6 and 12 months after transplantation. Amputation-free survival at 12 months among patients affected by CLI was set as a secondary endpoint.
3 574 Results of the NAPLES Study Figure 1. Study enrollment diagram of the Naples and Pietra Ligure Evaluation of Stem Cells study. Abbreviations: LDF, laser Doppler flowmetry; TcPO 2, transcutaneous oximetry. Data Management and Statistical Analysis Data were collected using paper-based case-report forms and computer database sheets. We calculated that a sample of 60 patients was required to detect an effect size of 0.55 between the study groups ( 0.05 and 0.70). We performed an analysis of variance with repeated measures to determine differences in within-subject effects over time, using the Bonferroni test. All reported p values are based on two-sided tests. Survival probability was evaluated with the Kaplan-Meier test. Data were analyzed with nquery Advisor 7.0 (Statistical Solutions, Sagus, MA, and SPSS software (SPSS, Chicago, RESULTS Patient and Demographics Seventy-six patients were enrolled from October 2008 to December Sixteen patients were discarded, leaving 60 patients for evaluation. The study enrollment diagram is shown in Figure 1, and the baseline features of claudicants and CLI patients are summarized in Table 2. Comorbidities and concomitant drug therapies did not differ significantly between the groups. All patients received antiplatelet or anticoagulant drugs throughout the study period. Procedural and Safety Results Marrow aspiration and injection were accomplished in the operating room on a single visit under local anesthesia. Patients tolerated the procedure well, and transient smooth sedation was used to facilitate the BM collection. There were no complications on the day of treatment, and there were no deaths or severe procedure-related adverse events after 1 month from the procedure. No local complications at the iliac crest puncture or reinjection site of common femoral artery were observed. No local or systemic infective complications occurred. One patient in group 2 with previous history of myocardial ischemia and coronary artery bypass graft developed a nonfatal myocardial infarction 2 months after the procedure. Because of the history of the patient, the event was not considered related to the cell infusion. The patient is still alive and well 24 months after the procedure. Table 2. Baseline features of patients in the Naples and Pietra Ligure Evaluation of Stem Cells study Baseline characteristics of enrolled patients (n 60) Value Age, years Mean SD Sex Male 44 (73.3%) Female 16 (26.7%) Peripheral artery disease (Rutherford classification) Stage 3 10 of 60 (16.7%) Stage 4 21 of 60 (35.0%) Stage 5 29 of 60 (48.3%) Critical limb ischemia 50 of 60 (83.3%) Comorbidities Hypertension 36 of 60 (60.0%) Diabetes 39 of 60 (65.0%) Hyperlipidemia 24 of 60 (40.0%) Previous smokers 36 of 60 (60.0%) Coronary artery disease 38 of 60 (63.3%) Concomitant drug therapies Antiplatelet therapy 56 of 60 (93.3%) Anticoagulant therapy 4 of 60 (6.7%) Two patients in group 2 needed a humeral approach because of the presence of heavy scar and/or heavy calcifications at the level of Scarpa s triangle, without complications. Viability and Features of Infused Cells From each harvest, a small aliquot of cells was analyzed by cytofluorimeter to assess cell viability. Cell viability of infused cells (mean SD of all samples collected) was %. We also tested BM-derived blood for CD34 and CD146 markers. The mean number of CD34 infused cells was , corresponding to % of all BM-MNCs. CD146 infused cells were found to be % of all BM-MNCs (International Society for Hematotherapy and Graft Engineering protocol enumeration in a single platform). Primary Endpoints Almost all patients reported improvements of clinical symptoms, such as pain and TWD, with positive impact on their quality of life. Quantitative analysis of the laser Doppler imaging of the group 1 revealed a significant increase of blood flow at rest in ischemic limbs at 12 months (T 12 ) (laser Doppler basal oxygenation: T vs. T ; p.008 with adjustment for multiple comparisons; Fig. 2). Restoration of perfusion has also been evident from the blood flow measured for the lowered leg (laser Doppler basal poststimulus [LDBP]: T vs. T ; p.035 with adjustment for multiple comparisons). The significance of this measure was lower; however, we should take into account that the increase of LDBP is abnormal in a healthy patient, whereas it is considered a compensatory mechanism in a patient affected by vasculopathy. Therefore, the increase of LDBP confirmed the beneficial effect of infusion. Next, we considered the response in hyperemia conditions. Increasing local skin temperature leads to an increase in blood flow, avoiding the myogenic vessel tone, providing an effective method by which to assess the presence of microcirculatory modifications. A significant increase in these conditions was observed (laser Doppler with probe at 44 C: T vs. T ; p.04 with adjustment for multiple comparisons). STEM CELLS TRANSLATIONAL MEDICINE
4 Schiavetta, Maione, Botti et al. 575 Figure 2. Change in perfusion parameters in group 1: laser Doppler basal oxygenation flowmetry measurements at T0 (before transplantation), T6, and T12 (after transplantation) visualized as a box plot, including the median, the minimum, and the maximum data values (p.008; repeated-measures analysis of variance). The black dots are the two outliers (patients 12 and 25), representing the minimum and the maximum of perfusion measurements. Abbreviations: PU, perfusion units; T, time in months. Figure 3. Change in perfusion parameters in group 2: transcutaneous oximetry measurements at T0 (before transplantation), T6, and T12 (after transplantation) visualized as a box plot, including the median, the minimum, and the maximum data values (p.008; repeated-measures analysis of variance). Abbreviations: T, time in months; TcPO 2, transcutaneous oximetry. TcPO 2 of the patients in group 2 showed a significant increase in TcPO 2 at 12 months in ischemic limbs after the treatment (T vs. T ; p.008 with adjustment for multiple comparisons; Fig. 3). The results of measurement with LDF and TcPO 2 in claudicants and CLI patients are not presented separately because of the small number of claudicants (n 10), although all patients showed similar perfusion responses to cell infusion. With regard to the 10 patients affected by Rutherford category 3 PAD, there was a subjective improvement of TWD beginning approximately 3 months after transplantation, increasing at least threefold at 6 months in 80% of them (8 of 10). This finding is not meaningful, based on the small number of patients and on the subjective evaluations. Secondary Endpoint CLI patients were followed up until death or until amputation occurred over the time. There were eight major amputations (16.6%) and four deaths (8.3%) in the period considered. We then calculated the amputation-free survival longitudinally and generated a Kaplan-Meier plot. As shown, the amputation-free survival in CLI patients (n 50) was 75.2% at 12 months after the treatment (Fig. 4), indicating that the risk of death and/or major amputation decreased in transplanted patients compared with natural evolution of the disease, in which 30% of patients will face amputation and 25% will die after 1 year, as already reported in above-mentioned TASC II Guidelines.
5 576 Results of the NAPLES Study Figure 4. Amputation-free survival. The Kaplan-Meier curve describes the amputation-free survival after 12 months among all critical limb ischemia subjects enrolled (n 50). Abbreviations: CI, confidence interval; std. err, standard error; surv, survival. DISCUSSION With the aging of Western population, PAD in general and CLI in particular are going to become more demanding problems for health care programs. Many patients unfit for surgery and/or an endovascular approach will face major amputation, further increasing social costs of the disease. This phase II multicenter clinical study confirmed the long-term beneficial effects of cellular therapy in patients with PAD. In fact, ischemia is a potent stimulus to increase the oxygen delivery via a network of collateral vessels and to stimulate angiogenesis [45, 46], but this natural capability is impaired in CLI patients [47, 48]. Intra-arterial infusion of BM-derived stem cells seems to be a safe procedure, confirming the findings of other studies [12], and it is also a promising tool in the hands of vascular specialists. No malignant tumor was clinically identified during the study period, and this outcome confirms data from other studies [39, 49]. Considering the perfusion analysis, the improvement of peripheral perfusion was confirmed both by LDF and TcPO 2 measurements, and it seemed to persist for at least 12 months after the treatment. Looking at the trend after 18 months, a decrease of the values after that time was observed and could be due to the progression of the disease (data not shown). This decrease has been already stated by others [49]. Thus, the option to retreat those patients showing a negative trend of the perfusion after 18 months can be taken into account. The 75% amputation-free survival recorded at 1 year among no-option CLI patients in our study appears to be promising compared with the natural evolution of CLI disease and the mean survival probability in this class of patients, and it is similar to the findings of a recent study in PAD patients treated with intramuscular BM-MNC infusion [12]. The procedure seems also to have beneficial effects on claudicants (Rutherford category 3), because the majority of enrolled patients of this category reported a marked increase in their TWD, although these data are based on subjective reports. We can hypothesize in the future a more active role of this therapy in claudicants, since this option does not exclude the possibility of resorting to subsequent surgical or endovascular approaches. We decided to not include the record of the ankle-brachial index for two reasons: (a) the measurements are operator-biased, and (b) the tibial vessels are incompressible in many diabetic patients. CONCLUSION The NAPLES study revealed that intra-arterial transplantation of BM-derived stem cells is beneficial in PAD patients, increasing STEM CELLS TRANSLATIONAL MEDICINE
6 Schiavetta, Maione, Botti et al. 577 the percentage of amputation-free survival in CLI patients at 1 year. Although both subjective and objective parameters of limb ischemia noticeably improved following cells transplantation, the real efficacy needs to be evaluated in larger groups. However, we have to take in account that robust cellular trials in CLI patients are complicated by severe comorbidities. For what concerns new strategies of the research, a promising tool could come from the use of superparamagnetic iron oxide nanoparticles (SPIONs) or carbon nanotubes (CNTs). In fact, researchers have shown that SPION- or CNT-labeled stem cells can be addressed to target tissue if submitted to magnetic gradients, increasing the number of stem cells within target tissues [50, 51]. Bone marrow transplantation in CLI patients is to our knowledge a safe procedure, improves tissue perfusion, and obtains high amputation-free survival rates. ACKNOWLEDGMENTS We are grateful to the Fondazione Luigi Califano, Fondazione Banco Napoli, and Istituto Superiore di Sanità, which gave us the support needed to perform the research. Special thanks go to Paola Mantovano and Giuseppe Sica, who helped us in coordinating the clinical trial. AUTHOR CONTRIBUTIONS A. Schiavetta and G.C.: conception and design, data assembly, interpretation and manuscript writing, final approval of manuscript; C.M., C.B., G.M., A.G., L.L., S.P.: data collection and assembly, data analysis and interpretation, final approval of manuscript; S.L. and A. Silvestroni: provision and treatment of patients and data collection, final approval of manuscript; G.S.: data analysis, conception and design, final approval of manuscript; V.S.: conception and design, financial support, final approval of manuscript. DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST The authors indicate no potential conflicts of interest. REFERENCES 1 Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/ AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery/ Society for Vascular Surgery, Society For Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/ AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; Transatlantic Inter-society Consensus; and Vascular Disease Foundation. Circulation 2006;113:e463 e Norgren L, Hiatt WR, Dormandy JA et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007;45(suppl S):S5 S67. 3 Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275: Shi Q, Rafii S, Wu MH et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998;92: Asahara T, Masuda H, Takahashi T et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85: Crosby JR, Kaminski WE, Schatteman G et al. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res 2000;87: Sprengers RW, Lips DJ, Moll FL et al. Progenitor cell therapy in patients with critical limb ischemia without surgical options. Ann Surg 2008;247: Kalka C, Masuda H, Takahashi T et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 2000;97: Yamaguchi J, Kusano KF, Masuo O et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 2003;107: Tateishi-Yuyama E, Matsubara H, Murohara T et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet 2002;360: Lu D, Chen B, Liang Z et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: A double-blind, randomized, controlled trial. Diabetes Res Clin Pract 2011;92: Walter DH, Krankenberg H, Balzer JO et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: A randomized start, placebo-controlled pilot trial (PROVASA). Circ Cardiovasc Interv 2011;4: Kawamoto A, Katayama M, Handa N et al. Intramuscular transplantation of G-CSF mobilized CD34( ) cells in patients with critical limb ischemia: A phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial. STEM CELLS 2009;27: Ozawa T, Kato K, Sanada H et al. Marked decrease of plasma VEGF after implantation of autologous bone marrow mononuclear cells in a patient with critical limb ischemia: A case report. Angiology 2006;57: Saigawa T, Kato K, Ozawa T et al. Clinical application of bone marrow implantation in patients with arteriosclerosis obliterans, and the association between efficacy and the number of implanted bone marrow cells. Circ J 2004;68: Lenk K, Adams V, Lurz P et al. Therapeutical potential of blood-derived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaemia. Eur Heart J 2005;26: Amann B, Luedemann C, Ratei R et al. Autologous bone marrow cell transplantation increases leg perfusion and reduces amputations in patients with advanced critical limb ischemia due to peripheral artery disease. Cell Transplant 2009;18: Burt RK, Testori A, Oyama Y et al. Autologous peripheral blood; CD133 cell implantation for limb salvage in patients with critical limb ischemia. Bone Marrow Transplant 2010; 45: Cobellis G, Silvestroni A, Lillo S et al. Long-term effects of repeated autologous transplantation of bone marrow cells in patients affected by peripheral arterial disease. Bone Marrow Transplant 2008;42: De Vriese AS, Billiet J, Van Droogenbroeck J et al. Autologous transplantation of bone marrow mononuclear cells for limb ischemia in a Caucasian population with atherosclerosis obliterans. J Intern Med 2008;263: Durdu S, Akar AR, Arat M et al. Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II III thromboangiitis obliterans. J Vasc Surg 2006; 44: Gu YQ, Zhang J, Guo LR et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chin Med J 2008;121: Hernández P, Cortina L, Artaza H et al. Autologous bone-marrow mononuclear cell implantation in patients with severe lower limb ischaemia: A comparison of using blood cell separator and Ficoll density gradient centrifugation. Atherosclerosis 2007;194:e52 e Horie T, Onodera R, Akamastu M et al. Long-term clinical outcomes for patients with lower limb ischemia implanted with G-CSF-mobilized autologous peripheral blood mononuclear cells. Atherosclerosis 2010;208: Kajiguchi M, Kondo T, Izawa H et al. Safety and efficacy of autologous progenitor
7 578 Results of the NAPLES Study cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. Circ J 2007;71: Kawamura A, Horie T, Tsuda I et al. Clinical study of therapeutic angiogenesis by autologous peripheral blood stem cell (PBSC) transplantation in 92 patients with critically ischemic limbs. J Artif Organs 2006;9: Koshikawa M, Shimodaira S, Yoshioka T et al. Therapeutic angiogenesis by bone marrow implantation for critical hand ischemia in patients with peripheral arterial disease: A pilot study. Curr Med Res Opin 2006;22: Lara-Hernandez R, Lozano-Vilardell P, Blanes P et al. Safety and efficacy of therapeutic angiogenesis as a novel treatment in patients with critical limb ischemia. Ann Vasc Surg 2010;24: Matoba S, Tatsumi T, Murohara T et al. TACT Follow-up Study Investigators. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J 2008;156: Miyamoto K, Nishigami K, Nagaya N et al. Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans. Circulation 2006;114: Moriya J, Minamino T, Tateno K et al. Long-term outcome of therapeutic neovascularization using peripheral blood mononuclear cells for limb ischemia. Circ Cardiovasc Interv 2009;2: Motukuru V, Suresh KR, Vivekanand V et al. Therapeutic angiogenesis in Buerger s disease (thromboangiitis obliterans) patients with critical limb ischemia by autologous transplantation of bone marrow mononuclear cells. J Vasc Surg 2008;48(suppl 6):53S 60S. 33 Saito Y, Sasaki K, Katsuda Y et al. Effect of autologous bone-marrow cell transplantation on ischemic ulcer in patients with Buerger s disease. Circ J 2007;71: Wester T, Jørgensen JJ, Stranden E et al. Treatment with autologous bone marrow mononuclear cells in patients with critical lower limb ischaemia. Scand J Surg 2008;97: Huang P, Li S, Han M et al. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005;28: Huang PP, Yang XF, Li SZ et al. Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thromb Haemost 2007;98: Procházka V, Gumulec J, Jalůvka F et al. Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer. Cell Transplant 2010;19: Kolvenbach R, Kreissig C, Cagiannos C et al. Intraoperative adjunctive stem cell treatment in patients with critical limb ischemia using a novel point-of-care device. Ann Vasc Surg 2010;24: Iafrati MD, Hallett JW, Geils G et al. Early results and lessons learned from a multicenter, randomized, double-blind trial of bone marrow aspirate concentrate in critical limb ischemia. J Vasc Surg 2011;54: Bartsch T, Brehm M, Zeus T et al. Transplantation of autologous mononuclear bone marrow stem cells in patients with peripheral arterial disease (the TAM-PAD study). Clin Res Cardiol 2007;96: Van Tongeren RB, Hamming JF, Fibbe WE et al. Intramuscular or combined intramuscular/intra-arterial administration of bone marrow mononuclear cells: A clinical trial in patients with advanced limb ischemia. J Cardiovasc Surg (Torino) 2008;49: Gu Y, Zhang J, Qi L. A clinical study on implantation of autologous bone marrow mononuclear cells after bone marrow stimulation for treatment of lower limb ischemia [in Chinese]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2006;20: Sprengers RW, Moll FL, Teraa M et al. Rationale and design of the JUVENTAS Trial for repeated intra-arterial infusion of autologous bone-marrow derived mononuclear cells in patients with critical limb ischemia. J Vasc Surg 2010;51: Powell RJ, Comerota AJ, Berceli SA et al. interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia. J Vasc Surg 2011;54: Kilian JG, Keech A, Adams MR. Coronary collateralization: Determinants of adequate distal vessel filling after arterial occlusion. Coron Artery Dis 2002;13: Wahlberg E. Angiogenesis and arteriogenesis in limb ischemia. J Vasc Surg 2003;38: Cetrulo CL, Jr., Knox KR, Brown DJ et al. Stem cells and distraction osteogenesis: Endothelial progenitor cells home to the ischemic generate in activation and consolidation. Plast Reconstr Surg 2005;116: ; discussion De Vivo S, Palmer-Kazen U, Kalin B et al. Risk factors for poor collateral development in claudication. Vasc Endovascular Surg 2005;39: Idei N, Soga J, Hata T et al. Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: A comparison of atherosclerotic peripheral arterial disease and Buerger disease. Circ Cardiovasc Interv 2011;4: Kyrtatos PG, Lehtolainen P, Junemann- Ramirez M et al. Magnetic tagging increases delivery of circulating progenitors in vascular injury. JACC Cardiovasc Interv 2009;2: Vittorio O, Quaranta P, Raffa V et al. Magnetic carbon nanotubes: A new tool for shepherding mesenchymal stem cells by magnetic fields. Nanomedicine (Lond) 2011;6: STEM CELLS TRANSLATIONAL MEDICINE
Topic: Stem-cell Therapy for Peripheral Arterial Disease Date of Origin: September 29, Section: Medicine Last Reviewed Date: October 2013
Medical Policy Manual Topic: Stem-cell Therapy for Peripheral Arterial Disease Date of Origin: September 29, 2011 Section: Medicine Last Reviewed Date: October 2013 Policy No: 141 Effective Date: January
More informationStem-cell Therapy for Peripheral Arterial Disease
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationAutologous Bone Marrow Mononuclear Cells Transplant in Patients With Critical Leg Ischemia: Preliminary Clinical Results
ARTIcle Autologous Bone Marrow Mononuclear Cells Transplant in Patients With Critical Leg Ischemia: Preliminary Clinical Results Min Li, 1 Hua Zhou, 2 Xing Jin, 2 Mo Wang, 2 Shiyi Zhang, 2 Lei Xu 2 Abstract
More informationMEDICAL POLICY POLICY TITLE STEM-CELL THERAPY FOR PERIPHERAL ARTERIAL DISEASE POLICY NUMBER MP-2.089
Original Issue Date (Created): April 24, 2012 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY Treatment of peripheral arterial disease, including critical
More informationStem-Cell Therapy for Peripheral Arterial Disease. Description
Page: 1 of 12 Last Review Status/Date: September 2015 Description Critical limb ischemia due to peripheral arterial disease (PAD) results in pain at rest, ulcers, and significant risk for limb loss. Injection
More informationNo option-patients : Is angiogenesis with gene or cell therapy still an option?
No option-patients : Is angiogenesis with gene or cell therapy still an option? Professor Sigrid Nikol Clinical and Interventional Angiology Asklepios-Klinik St. Georg Hamburg, Germany Angiogenic gene
More informationPopulations Interventions Comparators Outcomes Individuals: With peripheral arterial disease
Protocol Stem Cell Therapy for Peripheral Arterial Disease (80155) Medical Benefit Effective Date: 10/01/11 Next Review Date: 07/18 Preauthorization No Review Dates: 07/11, 07/12, 07/13, 07/14, 07/15,
More informationCell Therapy for Peripheral Arterial Disease
Medical Policy Manual Medicine, Policy No. 141 Cell Therapy for Peripheral Arterial Disease Next Review: October 2018 Last Review: October 2017 Effective: December 1, 2017 IMPORTANT REMINDER Medical Policies
More informationCorporate Medical Policy
Corporate Medical Policy Stem-cell Therapy for Peripheral Arterial Disease File Name: Origination: Last CAP Review: Next CAP Review: Last Review: stem_cell_therapy_for_peripheral_arterial_disease 7/2011
More informationIntra-arterial Allogeneic Mesenchymal Stem Cells for Critical Limb Ischemia are Safe and Efficacious: Report of a Phase I Study
World J Surg (2013) 37:915 922 DOI 10.1007/s00268-012-1892-6 Intra-arterial Allogeneic Mesenchymal Stem Cells for Critical Limb Ischemia are Safe and Efficacious: Report of a Phase I Study Anjan Kumar
More informationNational Clinical Conference 2018 Baltimore, MD
National Clinical Conference 2018 Baltimore, MD No relevant financial relationships to disclose Wound Care Referral The patient has been maximized from a vascular standpoint. She has no other options.
More informationUSWR 23: Outcome Measure: Non Invasive Arterial Assessment of patients with lower extremity wounds or ulcers for determination of healing potential
USWR 23: Outcome Measure: Non Invasive Arterial Assessment of patients with lower extremity wounds or ulcers for determination of healing potential MEASURE STEWARD: The US Wound Registry [Note: This measure
More informationFinancial Disclosures. Bone Marrow Mononuclear Cells. Cell Based Therapies: What Do They Do and Will They Work in CLI?
Cell Based Therapies: What Do They Do and Will They Work in CLI? None Financial Disclosures Michael P. Murphy, MD The Vascular and Cardiac Adult Stem Cell Therapy Center Indiana University School of Medicine
More informationDisclosures. Critical Limb Ischemia. Vascular Testing in the CLI Patient. Vascular Testing in Critical Limb Ischemia UCSF Vascular Symposium
Disclosures Vascular Testing in the CLI Patient None 2015 UCSF Vascular Symposium Warren Gasper, MD Assistant Professor of Surgery UCSF Division of Vascular Surgery Critical Limb Ischemia Chronic Limb
More informationJohn E. Campbell, MD. Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division
John E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division John Campbell, MD For the 12 months preceding this CME activity,
More informationProspects of Adult Stem cells therapy in Peripheral Vascular Diseases
BJMP 2010;3(4):a345 Review Article Prospects of Adult Stem cells therapy in Peripheral Vascular Diseases Jayprakash Gopall, Wen Huang and Yu Zhao ABSTRACT Peripheral Vascular Disease (PVD) is a growing
More informationPractical Point in Holistic Diabetic Foot Care 3 March 2016
Diabetic Foot Ulcer : Vascular Management Practical Point in Holistic Diabetic Foot Care 3 March 2016 Supapong Arworn, MD Division of Vascular and Endovascular Surgery Department of Surgery, Chiang Mai
More informationPractical Point in Diabetic Foot Care 3-4 July 2017
Diabetic Foot Ulcer : Role of Vascular Surgeon Practical Point in Diabetic Foot Care 3-4 July 2017 Supapong Arworn, MD Division of Vascular and Endovascular Surgery Department of Surgery, Chiang Mai University
More informationDue to Perimed s commitment to continuous improvement of our products, all specifications are subject to change without notice.
A summary Disclaimer The information contained in this document is intended to provide general information only. It is not intended to be, nor does it constitute, medical advice. Under no circumstances
More informationHypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis
Cryoplasty or Conventional Balloon Post-dilation of Nitinol Stents For Revascularization of Peripheral Arterial Segments Background: Diabetes mellitus is associated with increased risk of in-stent restenosis
More information3-year results of the OLIVE registry:
3-year results of the OLIVE registry: A prospective multicenter study in patients with critical limb ischemia Osamu Iida, MD Kansai Rosai Hospital Cardiovascular Center Amagasaki, Hyogo, Japan Disclosure
More informationCurrent Vascular and Endovascular Management in Diabetic Vasculopathy
Current Vascular and Endovascular Management in Diabetic Vasculopathy Yang-Jin Park Associate professor Vascular Surgery, Samsung Medical Center Sungkyunkwan University School of Medicine Peripheral artery
More informationIntroduction. Risk factors of PVD 5/8/2017
PATHOPHYSIOLOGY AND CLINICAL FEATURES OF PERIPHERAL VASCULAR DISEASE Dr. Muhamad Zabidi Ahmad Radiologist and Section Chief, Radiology, Oncology and Nuclear Medicine Section, Advanced Medical and Dental
More informationPeripheral Arterial Disease: the growing role of endovascular management
Peripheral Arterial Disease: the growing role of endovascular management Poster No.: C-1931 Congress: ECR 2012 Type: Educational Exhibit Authors: E. M. C. Guedes Pinto, E. Rosado, D. Penha, P. Cabral,
More informationLong-term effects of repeated autologous transplantation of bone marrow cells in patients affected by peripheral arterial disease
(2008) 42, 667 672 & 2008 Macmillan Publishers Limited All rights reserved 0268-3369/08 $32.00 www.nature.com/bmt ORIGINAL ARTICLE Long-term effects of repeated autologous transplantation of bone marrow
More informationPeripheral Arterial Disease Extremity
Peripheral Arterial Disease Lower Extremity 05 Contributor Dr Steven Chong Advisors Dr Ashish Anil Dr Tay Jam Chin Introduction Risk Factors Clinical Presentation Classification History PHYSICAL examination
More informationLong-Term Results of Treatment for Critical Limb Ischemia
2015 Annals of Vascular Diseases doi:10.3400/avd.oa.15-00074 Original Article Long-Term Results of Treatment for Critical Limb Ischemia Takuya Miyahara, MD, PhD, 1 Masamitsu Suhara, MD, 1 Yoko Nemoto,
More informationUpper extremity ischemia treated with tissue repair cells from adult bone marrow
Upper extremity ischemia treated with tissue repair cells from adult bone marrow Anthony J. Comerota, MD, FACS, FACC, RVT, a,b Angie Link, RN, BSN, a Judy Douville, MA, c and Elmar R. Burchardt, MD, PhD,
More informationReview Article Clinical Application of Vascular Regenerative Therapy for Peripheral Artery Disease
Hindawi Publishing Corporation BioMed Research International Volume 2013, Article ID 179730, 6 pages http://dx.doi.org/10.1155/2013/179730 Review Article Clinical Application of Vascular Regenerative Therapy
More informationPeripheral Artery Disease Compendium. Modulating the Vascular Response to Limb Ischemia. Angiogenic and Cell Therapies
Peripheral Artery Disease Compendium Circulation Research Compendium on Peripheral Artery Disease Epidemiology of Peripheral Artery Disease Pathogenesis of the Limb Manifestations and Exercise Limitations
More informationDo the newest grafts achieve comparable results to saphenous vein bypass? THE HEPARIN-BONDED eptfe GRAFT. C. Pratesi
Do the newest grafts achieve comparable results to saphenous vein bypass? THE HEPARIN-BONDED eptfe GRAFT C. Pratesi Department of Vascular Surgery University of Florence-Italy www.chirvasc-unifi.it FEMORO-POPLITEAL
More informationTreatment Strategies For Patients with Peripheral Artery Disease
Treatment Strategies For Patients with Peripheral Artery Disease Presented by Schuyler Jones, MD Duke University Medical Center & Duke Clinical Research Institute AHRQ Comparative Effectiveness Review
More informationCRITICAL LIMB ISCHEMIA UNITED STATES EPIDEMIOLOGY TABLE OF CONTENTS
CRITICAL LIMB ISCHEMIA UNITED STATES EPIDEMIOLOGY TABLE OF CONTENTS CRITICAL LIMB ISCHEMIA... 1 CONCLUSION... 9 U.S. CRITICAL LIMB ISCHEMIA PREVALENCE... 9 MARKET OPPORTUNITY ENDOVASCULAR... 9 MARKET OPPORTUNITY
More informationPrognostic Factors of Critical Limb Ischemia After Autologous Bone Marrow Implantation
J Cardiol 2007 Oct; 504: 235 242 Prognostic Factors of Critical Limb Ischemia After Autologous Bone Marrow Implantation 1 1 1 2 2 1 Masato Kiminori Ken Keita Toshiki Noboru Takao Masutaka Fuyuki Manabu
More informationJohn E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division
John E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division John Campbell, MD For the 12 months preceding this CME activity,
More informationThe Struggle to Manage Stroke, Aneurysm and PAD
The Struggle to Manage Stroke, Aneurysm and PAD In this article, Dr. Salvian examines the management of peripheral arterial disease, aortic aneurysmal disease and cerebrovascular disease from symptomatology
More informationObjective assessment of CLI patients Hemodynamic parameters
Objective assessment of CLI patients Hemodynamic parameters Worth anything in end stage patients? Marianne Brodmann Angiology, Medical University Graz, Austria Disclosure Speaker name: Marianne Brodmann
More informationUtility of Exercise-Induced Zero TBI Sign in Patients on Maintenance Hemodialysis
2016 Annals of Vascular Diseases doi:10.3400/avd.oa.16-00074 Original Article Utility of Exercise-Induced Zero TBI Sign in Patients on Maintenance Hemodialysis Kazuo Tsuyuki, CVT, PhD, 1 Kenji Kohno, PhD,
More informationSAFETY AND EFFECTIVENESS OF ENDOVASCULAR REVASCULARIZATION FOR PERIPHERAL ARTERIAL OCCLUSIONS
SAFETY AND EFFECTIVENESS OF ENDOVASCULAR REVASCULARIZATION FOR PERIPHERAL ARTERIAL OCCLUSIONS LIBBY WATCH, MD MIAMI VASCULAR SPECIALISTS MIAMI CARDIAC & VASCULAR INSTITUTE FINANCIAL DISCLOSURES None 2
More informationEvidence-Based Optimal Treatment for SFA Disease
Evidence-Based Optimal Treatment for SFA Disease Endo first Don t burn surgical bridge Don t stent if possible Javairiah Fatima, MD Assistant Professor of Surgery Division of Vascular and Endovascular
More informationClinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease
Cronicon OPEN ACCESS EC NEUROLOGY Research Article Clinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease Jin Ok Kim, Hyung-IL Kim, Jae Guk Kim, Hanna Choi, Sung-Yeon
More informationInterventional Treatment First for CLI
Interventional Treatment First for CLI Patrick Alexander, MD, FACC, FSCAI Interventional Cardiology Medical Director, Critical Limb Clinic Providence Heart Institute, Southfield MI 48075 Disclosures Consultant
More informationThe results of EVT for Chronic Aortic Occlusion - a multicenter retrospective study - Taku Kato, MD Rakuwakai Otowa Hospital, Kyoto, Japan
The results of EVT for Chronic Aortic Occlusion - a multicenter retrospective study - Taku Kato, MD Rakuwakai Otowa Hospital, Kyoto, Japan COI disclosure Disclosure Speaker name: Taku Kato... I have the
More informationDiagnosis and Endovascular Treatment of Critical Limb Ischemia: What You Need to Know S. Jay Mathews, MD, MS, FACC
Diagnosis and Endovascular Treatment of Critical Limb Ischemia: What You Need to Know S. Jay Mathews, MD, MS, FACC Interventional Cardiologist/Endovascular Specialist Bradenton Cardiology Center Bradenton,
More informationPotential Conflicts of Interest
DES-BTK: A Prospective, Double-Blind Randomized Trial of Polymer-Free Sirolimus-Eluting Stents Compared to Bare Metal Stents in Patients with Infrapopliteal Disease Aljoscha Rastan, MD, Gunnar Tepe, MD,
More informationUC SF. Disclosures. Vascular Assessment of the Diabetic Foot. What are the best predictors of wound healing? None. Non-Invasive Vascular Studies
Disclosures Vascular Assessment of the Diabetic Foot What are the best predictors of wound healing? None Shant Vartanian MD Assistant Professor of Vascular Surgery UCSF Vascular Symposium April 20, 2013
More informationFemoropopliteal Above-Knee Bypass: The True Results
Femoropopliteal Above-Knee Bypass: The True Results Lise Pyndt Jørgensen, Camilla Rasmussen & Torben V Schroeder Rigshospitalet and University of Copenhagen, DENMARK Treatment options in the femoropopliteal
More informationPAD and CRITICAL LIMB ISCHEMIA: EVALUATION AND TREATMENT 2014
PAD and CRITICAL LIMB ISCHEMIA: EVALUATION AND TREATMENT 2014 Van Crisco, MD, FACC, FSCAI First Coast Heart and Vascular Center, PLLC Jacksonville, FL 678-313-6695 Conflict of Interest Bayer Healthcare
More informationCell-Based Therapies for Peripheral Arterial Disease
Journal of Stem Cell Research & Therapy ISSN: 2157-7633 Journal of Stem Cell Research & Therapy Fujita and Kawamoto, 2014, 4:9 DOI: 10.4172/2157- Review Article Cell-Based Therapies for Peripheral Arterial
More informationMaking the difference with Live Image Guidance
Live Image Guidance 2D Perfusion Making the difference with Live Image Guidance In Peripheral Arterial Disease Real-time results, instant assessment Severe foot complications the result of hampered blood
More informationIliac Crest: The Gold Standard
Iliac Crest: The Gold Standard Iliac crest is often considered the gold standard for harvesting. The iliac crest contains bone marrow which is a rich source of regenerative cells, including: Endothelial
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationDON T LET LEG PAIN BECOME A REAL THREAT.
DON T LET LEG PAIN BECOME A REAL THREAT. These three words have the power to change lives. Between 8 to 10 million Americans are estimated to suffer from poor blood flow to the legs and feet potentially
More informationPedal Bypass With Deep Venous Arterialization:
Pedal Bypass With Deep Venous Arterialization: Long Term Result For Critical Limb Ischemia With Unreconstructable Distal Arteries Pramook Mutirangura Professor of Vascular Surgery Faculty of Medicine Siriraj
More informationCell Therapy in Patients with Critical Limb Ischemia in a Pilot Randomized Controlled Trial
Original Article Cell Therapy in Patients with Critical Limb Ischemia in a Pilot Randomized Controlled Trial Behnam Molavi MD 1, Mohammad Reza Zafarghandi MD 1, Ehsan Aminizadeh MD 2, Seyyedeh-Esmat Hosseini
More informationThe present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio
The present status of selfexpanding and balloonexpandable tibial BMS and DES for CLI: Why and when to use Sean P Lyden MD Cleveland Clinic Cleveland, Ohio Disclosure Speaker name: Sean Lyden, MD I have
More information9/7/2018. Disclosures. CV and Limb Events in PAD. Challenges to Revascularization. Challenges. Answering the Challenge
Disclosures State-of-the-Art Endovascular Lower Extremity Revascularization Promotional Speaker Jansen Pharmaceutical Promotional Speaker Amgen Pharmaceutical C. Michael Brown, MD, FACC al Cardiology Associate
More informationOlive registry: 3-years outcome of BTK intervention in Japan. Osamu Iida, MD Kansai Rosai Hospital Amagasaki, Hyogo, Japan
Olive registry: 3-years outcome of BTK intervention in Japan Osamu Iida, MD Kansai Rosai Hospital Amagasaki, Hyogo, Japan What is the optimal treatment for the patient with critical limb ischemia (CLI)?
More informationDisclosures. Talking Points. An initial strategy of open bypass is better for some CLI patients, and we can define who they are
An initial strategy of open bypass is better for some CLI patients, and we can define who they are Fadi Saab, MD, FASE, FACC, FSCAI Metro Heart & Vascular Metro Health Hospital, Wyoming, MI Assistant Clinical
More informationLarry Diaz, MD, FSCAI Mehdi H. Shishehbor, DO, FSCAI
PAD Diagnosis Larry Diaz, MD, FSCAI Metro Health / University of Michigan Health, Wyoming, MI Mehdi H. Shishehbor, DO, FSCAI University Hospitals Harrington Heart & Vascular Institute, Cleveland, OH PAD:
More informationFor No-Option patients, there is now another option. Dr. Michael Lichtenberg, Klinikum Arsnberg, Germany
From No Hope to New Hope For No-Option patients, there is now another option. Dr. Michael Lichtenberg, Klinikum Arsnberg, Germany Our Unique Solution The LimFlow system leverages a scientifically proven
More informationCurrent developments in the use of stem cell for therapeutic neovascularisation: is the future therapy cell-free?
Published 17 December 2010, doi:10.4414/smw.2010.13130 Cite this as: Current developments in the use of stem cell for therapeutic neovascularisation: is the future therapy cell-free? Zijiang Yang a, Stefano
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationPerfusion Assessment in Chronic Wounds
Perfusion Assessment in Chronic Wounds American Society of Podiatric Surgeons Surgical Conference September 22, 2018 Michael Maier, DPM, FACCWS Cardiovascular Medicine Cleveland Clinic Disclosures Speaker,
More informationClinical Approach to CLI and Related Diagnostics: What You Need to Know
Clinical Approach to CLI and Related Diagnostics: What You Need to Know Ido Weinberg, MD Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital None Disclosures Critical
More informationCLINICAL PRESENTATION AND RADIOLOGY QUIZ QUESTION
Donald L. Renfrew, MD Radiology Associates of the Fox Valley, 333 N. Commercial Street, Suite 100, Neenah, WI 54956 6/30/2012 Radiology Quiz of the Week # 79 Page 1 CLINICAL PRESENTATION AND RADIOLOGY
More information2-YEAR DATA SUPERA POPLITEAL REAL WORLD
2-YEAR DATA SUPERA POPLITEAL REAL WORLD Enrique M. San Norberto. Angiology and Vascular Surgery. Valladolid University Hospital. Valladolid. Spain. Disclosure Speaker name: ENRIQUE M. SAN NORBERTO I have
More informationRole of ABI in Detecting and Quantifying Peripheral Arterial Disease
Role of ABI in Detecting and Quantifying Peripheral Arterial Disease Difference in AAA size between US and Surgeon 2 1 0-1 -2-3 0 1 2 3 4 5 6 7 Mean AAA size between US and Surgeon Kathleen G. Raman MD,
More informationSTPH Clinic for Wound Care and Hyperbaric Medicine
STPH Clinic for Wound Care and Hyperbaric Medicine Ochsner/St. Tammany Partnership John Kessels, MD Medical Director St. Tammany Wound Center Chantal Lorio, DPM Associate Medical Director Ochsner Wound
More informationSurgery is and Remains the Gold Standard for Limb-Threatening Ischemia
Surgery is and Remains the Gold Standard for Limb-Threatening Ischemia Albeir Mousa, MD., FACS.,MPH., MBA Professor of Vascular and Endovascular Surgery West Virginia University Disclosure None What you
More informationLIBERTY 360 Study. 15-Jun-2018 Data 1. Olinic Dm, et al. Int Angiol. 2018;37:
LIBERTY 360 Study LIBERTY is a prospective, observational, multi-center study to evaluate procedural and long-term clinical and economic outcomes of endovascular device interventions in patients with symptomatic
More informationArterial Studies And The Diabetic Foot Patient
Arterial Studies And The Patient George L. Berdejo, BA, RVT, FSVU gberdejo@wphospital.org Disclosures I have nothing to disclose! Diabetes mellitus continues to grow in global prevalence and to consume
More informationClinical and morphological features of patients who underwent endovascular interventions for lower extremity arterial occlusive diseases
Original paper Clinical and morphological features of patients who underwent endovascular interventions for lower extremity arterial occlusive diseases Sakir Arslan, Isa Oner Yuksel, Erkan Koklu, Goksel
More informationWhat s New in the Management of Peripheral Arterial Disease
What s New in the Management of Peripheral Arterial Disease Sibu P. Saha, MD, MBA Professor of Surgery Chairman, Directors Council Gill Heart Institute University of Kentucky Lexington, KY Disclosure My
More informationWifi classification does not predict limb amputation risk in dialysis patients following critical limb ischemia revascularization
Wifi classification does not predict limb amputation risk in dialysis patients following critical limb ischemia revascularization A Sonetto, M Abualhin, M Gargiulo, GL Faggioli, A Stella Disclosure Speaker
More informationJAPAN PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA PREVALENCE AND INCIDENCE
JAPAN PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA PREVALENCE AND INCIDENCE Mary L. Yost 404-520-6652 , LLC 23 Ridge Rd Beaufort SC 29907 Copyright Pending 2017 All rights reserved, including the
More informationPeripheral Arterial Disease Management A Practical Guide for Internists. EFIM Vascular Working Group
2 Peripheral Arterial Disease Management A Practical Guide for Internists EFIM Vascular Working Group 1 Peripheral arterial disease (PAD) is a growing concern among our aging population. More than 27 million
More informationTABLE OF CONTENTS. 2. LOWER EXTREMITY PERIPHERAL ARTERIAL DISEASE 2.1. Epidemiology Risk Factors
LOWER EXTREMITY PAD The following is one of three extracted sections lower extremity, renal/mesenteric, and abdominal aortic of the ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral
More informationThe Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease
Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,
More informationComparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE) Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University Health System,
More informationMaximally Invasive Vascular Surgery for the Treatment of Critical Limb Ischemia
Maximally Invasive Vascular Surgery for the Treatment of Critical Limb Ischemia Traci A. Kimball, MD Department of Surgery Grand Rounds Septemember 13, 2010 Overview Defining Critical Limb Ischemia Epidemiology
More informationAutologous Bone Marrow Mononuclear Cell Implantation and Its Impact on the Outcome of Patients With Critical Limb Ischemia
Circ J 2017; 81: 1713 1720 doi: 10.1253/circj.CJ-17-0045 ORIGINAL ARTICLE Regenerative Medicine Autologous Bone Marrow Mononuclear Cell Implantation and Its Impact on the Outcome of Patients With Critical
More informationHistory & Literature Review
History & Literature Review History In the earliest stages of research, ACI Medical observed significant increases in arterial blood flow while testing a device that applied rapid, high level compressions
More informationEvolving Challenges in the Evaluation and Treatment of Lower Extremity PAD -- The Peripheral Academic Research Consortium (PARC)
Evolving Challenges in the Evaluation and Treatment of Lower Extremity PAD -- The Peripheral Academic Research Consortium (PARC) W. Schuyler Jones, MD FACC Director, Adult Cardiac Catheterization Laboratory
More informationRadiologic Evaluation of Peripheral Arterial Disease
January 2003 Radiologic Evaluation of Peripheral Arterial Disease Grace Tye, Harvard Medical School Year III Patient D.M. CC: 44 y/o male with pain in his buttocks Occurs after walking 2 blocks. Pain is
More informationCurrent Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis
Current Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis Osamu Iida, MD From the Kansai Rosai Hospital Cardiovascular Center, Amagasaki City, Japan. ABSTRACT: Approximately
More informationArthroplasty after previous surgery: previous vascular problems
Arthroplasty after previous surgery: previous vascular problems Jacques Menetrey & Victoria B. Duthon Centre de médecine de l appareil locomoteur et du sport Swiss Olympic medical Center Unité d Orthopédie
More informationMultidisciplinary approach to BTK Y. Gouëffic, MD, PhD
Multidisciplinary approach to BTK Y. Gouëffic, MD, PhD Department of vascular surgery, University Hospital of Nantes, France Response to the increased demand of hospital care Population is aging Diabetes
More informationPrevalence, Progression and Associated Risk Factors of Asymptomatic Peripheral Arterial Disease
ORIGINAL PAPER ORIGINAL PAPER The ANNALS of AFRICAN SURGERY www.annalsofafricansurgery.com Prevalence, Progression and Associated Risk Factors of Asymptomatic Peripheral Arterial Disease Nikita Mehta 1,
More informationStratifying Management Options for Patients with Critical Limb Ischemia: When Should Open Surgery Be the Initial Option for CLI?
Stratifying Management Options for Patients with Critical Limb Ischemia: When Should Open Surgery Be the Initial Option for CLI? Peter F. Lawrence, M.D. Gonda Vascular Center Division of Vascular Surgery
More informationVascular screening in diabetic patients: how aggressive should we be and when to intervene?
Vascular screening in diabetic patients: how aggressive should we be and when to intervene? Roberto Ferraresi Peripheral Interventional Unit Bergamo Italy Disclosure Speaker name: ROBERTO FERRARESI X X
More informationResults of an International Postmarketing Surveillance Study of pl-vegf165 Safety and Efficacy in 210 Patients with Peripheral Arterial Disease
Am J Cardiovasc Drugs (2017) 17:235 242 DOI 10.1007/s40256-016-0210-3 ORIGINAL RESEARCH ARTICLE Results of an International Postmarketing Surveillance Study of pl-vegf165 Safety and Efficacy in 210 Patients
More informationImaging Strategy For Claudication
Who are the Debators? Imaging Strategy For Claudication Duplex Ultrasound Alone is Adequate to Select Patients for Endovascular Intervention - Pro: Dennis Bandyk MD No Disclosures PRO - Vascular Surgeon
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Drug-eluting balloon angioplasty versus non-stenting balloon angioplasty for peripheral arterial disease of the lower limbs [Cochrane Protocol]
More informationA randomized comparison of endovascular versus surgery treatment of common femoral artery disease: Results from the TECCO trial
A randomized comparison of endovascular versus surgery treatment of common femoral artery disease: Results from the TECCO trial (TECCO randomized clinical trial, NCT01353651) Y. Gouëffic, N. Della Schiava,
More informationAngiosome concept myth or truth? Does it make a real difference in real world cases?
Angiosome concept myth or truth? Does it make a real difference in real world cases? Osamu Iida, MD, FACC Kansai Rosai Hospital Amagasaki, Hyogo, Japan Disclosure Speaker name:... I have the following
More informationPeripheral Vascular Disease Patient Awareness
Peripheral Vascular Disease Patient Awareness Interventional Radiology: your minimally invasive alternative www.cirse.org Cardiovascular and Interventional Radiological Society of Europe Cardiovascular
More informationClinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD
Clinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD Asan Medical Center, Heart Institute, University of Ulsan College of Medicine, Werk et al. Circulation Cardiovasc Intervent 2012
More informationAutologous Peripheral Blood Mononuclear Cell Implantation for Patients With Peripheral Arterial Disease Improves Limb Ischemia
Circ J 2005; 69: 1260 1265 Autologous Peripheral Blood Mononuclear Cell Implantation for Patients With Peripheral Arterial Disease Improves Limb Ischemia Akio Ishida, MD; Yusuke Ohya, MD; Hitoshi Sakuda,
More informationClinical and social consequences of Buerger disease
Clinical and social consequences of Buerger disease Takashi Ohta, MD, Hiroyuki Ishioashi, MD, Minoru Hosaka, MD, and Ikuo Sugimoto, MD, Aichi, Japan Purpose: This study was undertaken to assess the clinical
More information